Vaccine Production Core

$1,627,367U19FY2008AINIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 38219684 Paper 38196621 Paper 37873269 Paper 34556879 Paper 34282143 Paper 33818783 Paper 32817216 Paper 31959979 Paper 31812703 Paper 31153890 Paper 31048489 Paper 30943890 Paper 30940688 Paper 30413420 Paper 29765018 Paper 29679388 Paper 29263306 Paper 29122469 Paper 29017536 Paper 28826648 Paper 28794409 Paper 28783677 Paper 28513609 Paper 28490585 Paper 28202756 Paper 28123174 Paper 28003492 Paper 27942585 Paper 27919754 Paper 27876849 Paper 27723488 Paper 27430715 Paper 27381634 Paper 27173934 Paper 27072605 Paper 26862758 Paper 26700767 Paper 26697975 Paper 26544970 Paper 26512082 Paper 26399966 Paper 26355218 Paper 26238685 Paper 26202232 Paper 26192357 Paper 26157116 Paper 26018159 Paper 26010577 Paper 25903330 Paper 25897603 Paper 25855741 Paper 25590979 Paper 25572881 Paper 25567537 Paper 25503264 Paper 25407514 Paper 25340797 Paper 25274446 Paper 25212771 Paper 25135832 Paper 25121750 Paper 25105367 Paper 25092293 Paper 25080550 Paper 25054205 Paper 25028937 Paper 25017952 Paper 24981332 Paper 24928650 Paper 24920809 Paper 24910414 Paper 24837783 Paper 24820481 Paper 24786365 Paper 24743648 Paper 24723745 Paper 24670323 Paper 24662931 Paper 24648342 Paper 24614505 Paper 24614107 Paper 24554654 Paper 24491164 Paper 24465011 Paper 24457632 Paper 24352444 Paper 24336909 Paper 24299076 Paper 24260419 Paper 24244365 Paper 24237700 Paper 24204277 Paper 24145401 Paper 24139043 Paper 24131720 Paper 24086252 Paper 24023257 Paper 23966410 Paper 23941304 Paper 23936006

Abstract

Critical to the ultimate success of the CHAVI is the development of its capacity to rapidly move new discoveries and acquired technologies to testing in preclinical / clinical trials through collaboration with existing networks such as the HVTN, VRC, CAVD/Enterprise, and the NIH. In Year 3, CHAVI will ask critical questions with the current best vectors and inserts regarding insert immunogenicity and quality of the mucosal and systemic immune responses. The CHAVI Vaccine Production Core will coordinate and manage timelines required for preclinical studies in year 3.

View original record on NIH RePORTER →